Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH, 43210, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Columbus, OH, 43210, USA; Department of Biomedical Engineering, The Ohio State University, 140West 19th Avenue, Columbus, OH, 43210, USA; The Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Columbus, OH, 43210, USA.
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Columbus, OH, 43210, USA; The Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Columbus, OH, 43210, USA.
Pulm Pharmacol Ther. 2023 Apr;79:102196. doi: 10.1016/j.pupt.2023.102196. Epub 2023 Jan 20.
The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery during ARDS offers several potential advantages including limiting the off-target and off-organ effects and directly targeting the damaged and inflamed lung regions. In this review we summarize recent ARDS clinical trials using both systemic and pulmonary drug delivery. We then discuss the advantages of pulmonary drug delivery and potential challenges to its implementation. Finally, we discuss the use of nanoparticle drug delivery and surfactant-based drug carriers as potential strategies for delivering therapeutics to the injured lung in ARDS.
急性呼吸窘迫综合征（ARDS）是一种危及生命的疾病，可导致呼吸衰竭。尽管进行了大量的临床试验，但目前尚无针对 ARDS 的分子靶向药物治疗方法。ARDS 期间的药物输送具有挑战性，因为肺损伤的异质性以及水肿液和炎症对肺单位的阻塞。ARDS 期间的肺部药物输送具有多种潜在优势，包括限制非靶向和非器官作用，并直接靶向受损和发炎的肺部区域。在这篇综述中，我们总结了最近使用全身和肺部药物输送的 ARDS 临床试验。然后，我们讨论了肺部药物输送的优势以及实施肺部药物输送的潜在挑战。最后，我们讨论了使用纳米颗粒药物输送和基于表面活性剂的药物载体作为将治疗剂递送到 ARDS 受损肺部的潜在策略。
